---
abstract: Patients with advanced gastroesophageal cancer have poor survival with current
  therapy. Human epidermal growth factor receptor 2 HER2 represents a promising therapeutic
  target, but the optimal HER2 testing strategy is not yet defined.
authors: Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks
  JB, Shah MA and Barbashina V.
cancertypes: []
contact:
  email: ~
  name: Violetta Barbashina
counts:
  biosamples: 31
  samples_acgh: 31
  samples_ccgh: 0
  samples_wes: 0
  samples_wgs: 0
external_identifiers:
- pubmed:22032573
geo_data:
  geo_json:
    coordinates:
    - -74.01
    - 40.71
    type: Point
  info:
    city: New York City
    continent: North America
    country: United States
    label: New York City, United States, North America
    precision: city
journal: 'Arch Pathol Lab Med 135, 11 (2011): 1460-65.'
label: 'Tafe et al. (2011): Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal
  Cancer: Correlation Between ...'
notes: ~
pmid: 22032573
title: 'Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer:
  Correlation Between Immunohistochemistry and Fluorescence in Situ Hybridization.'
year: 2011
